title stringlengths 1 1.19k | keywords stringlengths 0 668 | concept stringlengths 0 909 | paragraph stringlengths 0 61.8k | PMID stringlengths 10 11 |
|---|---|---|---|---|
Results | PMC10106287 | |||
Clinical characteristics | Depression | PURGING | Participants have been described previously (Keel et al., Clinical features associated with binge eating, purging, and their combinationBDI, Beck Depression Inventory (Beck et al., * | PMC10106287 |
Gastric emptying | PURGING | Analyses of gastric emptying under the placebo condition appear in Associations between gastric emptying, binge eating, purging, and their combinationFor the Unconditional Growth Model, change in fit is compared to the Unconditional Means Model (results not included in table) for which BIC = 8686.70, and Deviance (para... | PMC10106287 | |
Subjective responses to the meal | gastrointestinal distress | PURGING | Models predicting gastrointestinal distress supported a main effect for purging [Gastric emptying was a significant predictor of gastrointestinal distress in the placebo condition [Participants endorsed | PMC10106287 |
Exploratory analyses of gut peptide responses | PD, gastrointestinal distress, eating disorder | PURGING | In prior analysis in this sample, we demonstrated significantly greater postprandial PYY release in PD compared to both control and BNp participants under the placebo condition (Keel et al., To understand whether PYY mediated the effects of medication and eating disorder features on gastrointestinal distress, we added ... | PMC10106287 |
Discussion | Gastroparesis, bloating, nausea, nonpurging, increases gastric motility, illness, self-induced vomiting, eating disorders, vomiting, Camilleri, upper gastrointestinal symptom, PD, gastrointestinal distress, gastroparesis, eating disorder, DSM-5 | GASTROPARESIS, TARDIVE DYSKINESIA, DYSFUNCTION, SAID, MITCHELL, GASTROPARESIS, PATHOLOGY, DELAYED GASTRIC EMPTYING, PURGING | We sought to determine whether delayed gastric emptying was associated with purging, binge eating, or both, and results supported a specific association with purging. In addition, delayed gastric emptying was associated with greater postprandial gastrointestinal distress, suggesting that a mechanical disruption in the ... | PMC10106287 |
Acknowledgements | This work was supported by funding from the National Institute of Mental Health 2R01MH061836; R01MH111263 (Keel), University of Iowa CTSA UL1RR024979 (Hunninghake), The Council on Research and Creativity at Florida State University (Keel), and the Bernice S. Weisman Fund at Beth Israel Deaconess Medical Center (Jimerso... | PMC10106287 | ||
References | PMC10106287 | |||
Background | A randomised trial of European Fans in Training (EuroFIT), a 12-week healthy lifestyle program delivered in 15 professional football clubs in the Netherlands, Norway, Portugal, and the United Kingdom, successfully increased physical activity and improved diet but did not reduce sedentary time. To guide future implement... | PMC10026416 | ||
Methods | RECRUITMENT | We analysed qualitative data implementation notes, observations of 29 of 180 weekly EuroFIT deliveries, semi-structured interviews with 16 coaches and 15 club representatives, and 30 focus group discussions with participants (15 post-program and 15 after 12 months). We descriptively analysed quantitative data on recrui... | PMC10026416 | |
Results | We successfully recruited clubs, coaches and men to EuroFIT though the draw of the football club seemed stronger in the UK and Portugal. Advertising that emphasized getting fitter, club-based deliveries, and not ‘standing out’ worked and attendance and fidelity were good, so that coaches in all countries were able to d... | PMC10026416 | ||
Conclusion | EuroFIT was delivered as planned by trained club coaches working flexibly in all countries. It worked as expected to attract men and support initiation and maintenance of changes in physical activity and diet but the use of bespoke, unstable, technologies was frustrating. Future deliveries should eliminate the focus on... | PMC10026416 | ||
Trial registration | ISRCTN81935608, registered 16/06/2015.
| PMC10026416 | ||
Supplementary Information | The online version contains supplementary material available at 10.1186/s12889-023-15419-y. | PMC10026416 | ||
Keywords | PMC10026416 | |||
Introduction | cancers | CANCERS, TYPE 2 DIABETES, DISEASES, CARDIOVASCULAR DISEASE | Low levels of physical activity and high levels spent in sedentary time are contributing to the increasing global prevalence of non-communicable diseases such as cardiovascular disease, type 2 diabetes and some cancers, [One approach to attracting men to lifestyle change is to offer programs in partnership with profess... | PMC10026416 |
The EuroFIT program: an overview | The EuroFIT program was designed to support men to: become more physically active and less sedentary; improve their diets; and maintain these changes over the long term. It was delivered over 12, weekly, 90-min sessions that combined ‘classroom’ discussion, including ‘tools’ for behaviour change, with group-based physi... | PMC10026416 | ||
Methods | PMC10026416 | |||
Process evaluation design | The mixed methods process evaluation reported here was embedded in the EuroFIT RCT (Trial registration ISRCTN81935608, registered 16/06/2015) [ | PMC10026416 | ||
Changes to protocol | MINOR, RECRUITMENT | In conducting analyses for this paper, we made some minor changes to methods described in the protocol.The protocol described eight methods, two of which (structured telephone questionnaire with participants opting out of the study and structured questionnaires to coaches on training and on program delivery) did not yi... | PMC10026416 | |
Data collection | Table Research objectives, Theory of Change element considered and data collection methods for the EuroFIT process evaluation | PMC10026416 | ||
Research team implementation notes | RECRUITMENT | Throughout the recruitment and delivery phases, the EuroFIT research team kept detailed notes on implementation. These notes were recorded in the minutes of regular meetings and provided data on issues that were faced. | PMC10026416 | |
Expressions of interest and | RECRUITMENT | Expressions of interest were captured via a web form, which provided data on the numbers of men interested in participating in EuroFIT. Potential participants were screened by telephone for eligibility from this database before recruitment began, as described elsewhere. [ | PMC10026416 | |
Participant questionnaires | All 1113 RCT participants (560 allocated to intervention and 554 to comparison group) were asked to complete self-report questionnaires at baseline, when the intervention group had finished the program, (post-program) and 12 months after it began (12-months). The intervention group participants were also asked to compl... | PMC10026416 | ||
Participant attendance | Club coaches were asked to keep a record of attendance at each of the 12 EuroFIT sessions, via an online database provided by the research team. | PMC10026416 | ||
Participants’ SitFIT and MatchFIT usage logs | Participants registered on the MatchFIT app and then SitFIT and MatchFIT usage data were collected remotely from users on a dedicated server. Data generated included logs of data uploads, error reports, user clicks, logins and logouts. Each item of logged data included a timestamp, information about the web browser and... | PMC10026416 | ||
Observation of sessions | Observations of EuroFIT sessions were conducted in each of the 15 clubs by members of the local research teams, aiming for two sessions per club. We aimed to observe session 4, which covers multiple topics and activities, and one of session 3 or 5–12 in each club. We avoided sessions 1 and 2 to allow groups time to ‘fo... | PMC10026416 | ||
Semi-structured interviews with coaches and football club representatives | We conducted semi-structured interviews with 16 coaches who delivered EuroFIT and with 15 football club representatives involved in managing EuroFIT when the program had been delivered.Interviews covered what they thought of the program, their experiences of what worked or did not work when launching EuroFIT, barriers ... | PMC10026416 | ||
Focus group discussions with participants | Focus groups were conducted in each football club with a sample of participants who attended six or more EuroFIT sessions at two time points, when the program ended and 12 months after the program started. We tried to recruit the same men at each time point. We prompted discussion on what men thought of the EuroFIT pro... | PMC10026416 | ||
Data analysis | ’ [ | Our approach to data analysis is described in detail in our protocol paper [Quantitative data were summarised using SPSS (v21) and reported descriptively. Qualitative data (study team notes, observations, interviews, focus groups) were analysed following a framework approach [Finally, to compare findings from different... | PMC10026416 | |
Informed consent and ethical approvals | When participants agreed to join the study, they completed and signed an informed consent form, in the presence of a trained researcher. Participants received information sheets explaining the study, its aims and procedures, and were encouraged to read and ask any questions they had. They were asked to provide consent ... | PMC10026416 | ||
Results | A summary of response rates by method can be found in Table
Response rates for survey and qualitative methods***Qualitative data extracts are labelled to indicate participant ID (P (participant); C (coach); and (club representative)), club (NOR1-3, UK1-5, POR1-3, NL1-4) and data source (PPFGD [post-program focus group... | PMC10026416 | ||
Discussion | RECRUITMENT, SAID, RECRUITMENT | Our analysis shows that EuroFIT was largely implemented as planned in professional football clubs in four countries, that coaches delivered the program as intended and that the program worked largely as expected for participants.The research project paid for deliveries of EuroFIT within the trial context which facilita... | PMC10026416 | |
Strengths and Limitations | A major strength of this study is that it analysed data from four countries, in fifteen club settings, and derived the findings from a large body of data collected through multiple methods, allowing for triangulation across data sources. The study also deliberately employed behaviour change strategies informed by conte... | PMC10026416 | ||
Conclusions | This paper has explored the processes through which EuroFIT achieved its outcomes and the extent to which the underpinning theory of change represented the program’s mechanisms of action. Through a mixed-methods approach, we have concluded that the theory of change is an effective representation of the EuroFIT program,... | PMC10026416 | ||
Acknowledgements | Mattias | We are grateful to participants who took part in the research, coaches and club managers at fifteen football clubs and UEFA’s Football and Social Responsibility department for supporting the proposal at bidding stage. Ciaran Clissman of Pintail Ltd managed the project and provided invaluable editorial input into the fu... | PMC10026416 | |
Authors’ contributions | CB, VP, NRC, EA, CG, KH, JGM, HM, MNS, HP, GCR, JR, OBR, MNS, MS, TVA, IVG, FVN, SW contributed to the analysis and interpretation of the data. CB, VP, NRC and SW conducted the triangulation phase of analysis. CB, VP, NRC and SW drafted the manuscript. All authors made contributions to the revision of the manuscript an... | PMC10026416 | ||
Funding | This project has received funding from the European Union’s Seventh Framework Program for research, technological development, and demonstration under grant agreement number 602170. The Health Services Research Unit, University of Aberdeen, receives core funding from the Chief Scientist Office of the Scottish Governmen... | PMC10026416 | ||
Availability of data and materials | The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request. | PMC10026416 | ||
Declarations | PMC10026416 | |||
Ethics approval and consent to participate | Ethical approvals for the RCT and the process evaluation were obtained from appropriate country-specific ethics committees (Ethics Committee of the VU University Medical Center [2015.184]; Regional Committees for Medical and Health Research Ethics, Norway [2015/1862]; Ethics Council of the Faculty of Human Kinetics, Un... | PMC10026416 | ||
Consent for publication | Not applicable. | PMC10026416 | ||
Competing interests | The authors declare that they have no competing interests. | PMC10026416 | ||
References | PMC10026416 | |||
Abstract | inflammation, Frailty, Thrombosis, postmyocardial infarction | INFLAMMATION, ATHEROSCLEROSIS, THROMBOSIS | Although inflammation is strongly associated with frailty, whether medications that lower inflammation decrease frailty is unclear and randomized trial evidence is scant. We sought to test whether canakinumab, a therapeutic monoclonal antibody that inhibits IL‐1β and reduces C‐reactive protein (CRP), can lower frailty ... | PMC10776110 |
Abbreviations | Thrombosis | OSTEOPOROTIC FRACTURES, THROMBOSIS | body mass indexCanakinumab ANti‐inflammatory Thrombosis Outcome StudyC‐reactive proteinfrailty indexhazard ratiointerleukin 6major adverse cardiovascular eventsmyocardial infarctionnonsteroidal anti‐inflammatory drugsStudy of Osteoporotic Fractures | PMC10776110 |
INTRODUCTION | thrombosis, Frailty | THROMBOSIS, EVENTS, SYNDROME | Frailty is a geriatric syndrome of vulnerability, common in older adults, that increases the risk of cardiovascular events, functional decline, morbidity, and mortality (Afilalo et al., Canakinumab is a therapeutic monoclonal antibody that targets IL‐1β blockade leading to reductions in both IL‐6 and the hepatic acute ... | PMC10776110 |
METHODS | PMC10776110 | |||
Trial design | The CANTOS has been described in detail previously (Ridker et al., | PMC10776110 | ||
Outcomes | The primary outcome of this study was incident frailty over the duration of the trial. Secondarily, we assessed change in mean frailty score over time and change in self‐reported functional ability using the EQ‐5D questions for mobility, self‐care, and usual activities. In an exploratory analysis, we examined change in... | PMC10776110 | ||
Frailty | weight loss, presbyopia | PRESBYOPIA | Although there are multiple tools that can be used to assess frailty, in CANTOS, we primarily defined frailty according to the accumulation of deficits definition of frailty developed by Rockwood and Mitnitski (To be included in the FI, variables must (1) be related to health status, (2) increase in prevalence with age... | PMC10776110 |
Functional impairment | Self‐reported items from the EQ‐5D‐3L instrument were used to identify impairment in mobility, self‐care, or usual activity. Each variable was assessed as “no problems,” “some problems,” or “unable.” | PMC10776110 | ||
Major cardiovascular events | stroke, cardiovascular death | STROKE, EVENTS | The primary endpoint of the trial was time to the composite endpoint of MI, stroke, or cardiovascular death. All events were adjudicated by an adjudication committee who were blinded to the trial‐group assignments (Ridker et al., | PMC10776110 |
Other covariates | At baseline, information on age, sex, race, ethnicity, smoking status, body mass index (BMI), and blood pressure was measured. | PMC10776110 | ||
Analytic plan | REGRESSION, EVENT, SECONDARY | Descriptive statistics of the sample were computed overall and by frailty status.The FI was first validated by assessing the association between FI level and risk of mortality over follow‐up using Cox regression (Searle et al., For the primary outcome of incident frailty, we excluded those who were frail at study basel... | PMC10776110 | |
RESULTS | Among 10,061 participants in CANTOS, 9942 (99%) had sufficient data to calculate an FI at baseline (Figure Table Baseline characteristics of 9942 CANTOS participants by frailty category at baseline.
Those who were prefrail and frail had a higher risk of mortality over the duration of the trial (Table | PMC10776110 | ||
Incident frailty | IL‐6 reduction | Of the 8620 participants who were not frail at baseline, 1080 (12.5%) became frail during the 5‐year follow‐up period. There was no difference in rate of incident frailty according to randomization over time, comparing those allocated to any dose of canakinumab as compared to placebo or in comparisons of each dose sepa... | PMC10776110 | |
Change in frailty score | Mean frailty scores increased from 0.12 at baseline to 0.14 at the end of the trial. There was no difference in mean frailty score between randomization groups over time (Figure Effect of canakinumab on change in mean frailty score ( | PMC10776110 | ||
Physical function | Overall, there was no difference in self‐reported mobility, self‐care, or usual activities over the follow‐up period in those assigned to active drug or placebo (all | PMC10776110 | ||
Major adverse cardiovascular events by baseline frailty | REGRESSION, REGRESSIONS | The primary trial outcome was rerun in the 9942 participants who had an FI available at baseline. Among those who were not frail 9.6% experienced a MACE outcome, while for those who were prefrail and frail, 15.8% and 27.4% experienced MACE, respectively. In the overall trial, the published HR (95% CI) compared with pla... | PMC10776110 | |
DISCUSSION | myocardial infarction, osteoarthritis, inflammation, mitochondrial dysfunction, anemia, proteotoxic stress, gout | MYOCARDIAL INFARCTION, OSTEOARTHRITIS, INFLAMMATION, ANEMIA, DISORDERS, LUNG CANCERS, SECONDARY, EVENTS, GOUT, MITOCHONDRIAL DYSFUNCTION, PATHOGENESIS | CANTOS has previously demonstrated that IL‐1b inhibition with canakinumab, compared with placebo, lowers the inflammatory biomarkers CRP and IL6 by 35 to 45 percent and significantly reduces rates of several clinical disorders associated with aging, including cardiovascular events, lung cancers, gout, anemia, and large... | PMC10776110 |
CONCLUSION | ATHEROSCLEROSIS | Among stable adult patients with atherosclerosis, random allocation to interleukin‐1b inhibition with canakinumab as compared to placebo did not lower risk of incident frailty over 5 years. More randomized data are needed to understand the role of targeted anti‐inflammatory medications for prevention of frailty and fun... | PMC10776110 | |
AUTHOR CONTRIBUTIONS | PMR | ARO, RB, and PMR were involved in concept and design. PMR was involved in data curation and resources & supervision. AT, JM, and TGT were involved in analysis. All authors were involved in interpretation and writing—review & editing. ARO was involved in writing—original draft. | PMC10776110 | |
FUNDING INFORMATION | RTI | Novartis funded the CANTOS trial and the statistical analyses conducted for this manuscript. This post‐hoc analysis was investigator initiated. The funders approved the manuscript but were not otherwise involved in the conduct of this study. Dr. Orkaby is funded by VA CSR&D CDA‐2 award IK2‐CX001800 and reports consulti... | PMC10776110 | |
CONFLICT OF INTEREST STATEMENT | None declared. | PMC10776110 | ||
Supporting information | APPENDIX |
Appendix S1
Click here for additional data file. | PMC10776110 | |
ACKNOWLEDGEMENTS | We are grateful to the participants in the CANTOS trial. | PMC10776110 | ||
DATA AVAILABILITY STATEMENT | Qualified external researchers may request access to patient‐level data and supporting clinical documents. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in li... | PMC10776110 | ||
REFERENCES | PMC10776110 | |||
Introduction | SD, anxiety | N,N-Dimethyltryptamine (DMT) is a serotonergic psychedelic that induces a rapid and transient altered state of consciousness when inhaled or injected via bolus administration. Its marked and novel subjective effects make DMT a powerful tool for the neuroscientific study of consciousness and preliminary results show its... | PMC10851633 | |
Materials and methods | PMC10851633 | |||
Study design | In a single-blind, placebo-controlled study using a within-subjects repeated measures design, 11 healthy volunteers received up to four different doses of bolus plus slow-rate infusions of DMT over 30 min. Dosing sessions were separated by at least 2 weeks. On dosing visits, EEG activity as well as subjective and auton... | PMC10851633 | ||
Dosing schedule | Different dose regimens were simulated based on a separate population pharmacokinetic reanalysis of data from a previous study (Dosing schedule of continuous IV infusions of DMT. Doses are expressed for DMT fumarate. A bolus injection was given over 30 s, followed by a saline flush over 15 s. The continuous slow-rate i... | PMC10851633 | ||
Study drugs | STERILE | On dosing days, DMT fumarate (Cole Parmer Instrument Company Limited, St Neots, Cambridgeshire, United Kingdom; Onyx Scientific, Sunderland, Tyne & Wear, United Kingdom) was reconstituted with saline to give a 5 mg/ml solution and sterile-filtered into sterile vials. To keep infusion rates equal across doses, DMT was d... | PMC10851633 | |
Participants | psychotic disorder, psychedelic drug, SD, psychiatric disorder, diabetes | DIABETES | Eleven healthy participants (seven male, four female, mean age ± SD = 37.09 ± 8.93 years, range = 26–51 years) took part in this study. Participants were recruited via word of mouth. Exclusion criteria for study participation were age <18, current or previously diagnosed psychiatric disorder, family history of psychoti... | PMC10851633 |
Study procedures | psychiatric | BLOOD | All volunteers attended a screening visit to determine eligibility to be enrolled in the study. During this visit, a physical examination (weight, ECG, blood pressure, heart rate (HR) and neurological examination) and routine blood test were performed, as well as a psychiatric interview (see ‘Participants’ for exclusio... | PMC10851633 |
Experience sampling of subjective effects | PMC10851633 | |||
Intensity | ’ | Subjective intensity of effects was assessed acutely via experience sampling from 8 min prior to 52 min after the start of the bolus injection. For this, audio prompts were played through headphones, and participants were instructed to verbally give subjective ratings of the intensity of the experience (from 0 = ‘no ef... | PMC10851633 | |
Anxiety | anxiety, ’ | Subjective ratings of anxiety were also collected every 4 min using a similar procedure (from 0 = ‘no anxiety’ to 10 = ‘most anxiety imaginable’) in order to assess the psychological safety of DMT infusions. | PMC10851633 | |
Retrospective assessments of subjective effects | PMC10851633 | |||
ASC and MEQ-30 | Auditory alterations, Oceanic boundlessness’, MEQ-30 | AUDITORY ALTERATION | Once the acute drug effects had subsided (~30 min following the end of administration), participants completed the altered states of consciousness (ASC) Scale and the Mystical Effects Questionnaire (MEQ-30). The ASC scale measures altered states of consciousness. The 94 items make up five dimensions (5D-ASC; ‘Oceanic b... | PMC10851633 |
Dynamic subjective effects | Meaningfulness, Auditory hallucinations, ’ | Additionally, participants were asked to retrospectively provide ratings of various dimensions of their experience over time (from 0 = ‘none/not at all’ to 10 = ‘an extreme amount/extremely’). These dimensions included ‘Immersion’, ‘Entity encounters’, ‘Ego dissolution’, ‘Visual imagery’, ‘Emotional experience’, ‘Audit... | PMC10851633 | |
Heart rate | HR was measured and monitored from 8 min before until 52 min after the beginning of the bolus injection with an E4 Empatica wristband (Empatica Srl, Milan, Italy) which participants wore on their wrist during the dosing period. The results reported here correspond to the recorded HR at 2-min intervals. | PMC10851633 | ||
Plasma DMT concentrations | BLOOD | Plasma levels of DMT were repeatedly assessed at baseline and 2, 5, 10, 20, 29, 32, 37, 40, 50, 60, 80, 100, 120, 150, and 180 min after the beginning of bolus injection of DMT. Blood samples (up to 6 ml) were collected into EDTA tubes, kept on wet ice, and centrifuged within 1h of collection. The harvested plasma was ... | PMC10851633 | |
Statistical analysis | anxiety, MEQ-30 | Linear mixed-effects models (LMMs) were constructed to test the relationship between doses, timepoints, and the response variables of intensity, anxiety, HR, DMT plasma concentrations, ASC scores and MEQ-30 scores. LMMs exhibit several advantages over repeated measures Analyses of Variance (ANOVAs) in dealing with the ... | PMC10851633 | |
Experience sampling of subjective effects | PMC10851633 | |||
Intensity | Substantial increases in intensity ratings were observed with all tested doses, as shown in | PMC10851633 | ||
Anxiety | anxiety | Overall, participants experienced low levels of anxiety before and throughout dosing indicating that extended administration of DMT was well tolerated ( | PMC10851633 | |
Retrospective assessments of subjective effects | PMC10851633 | |||
ASC and MEQ-30 | Auditory alterations, Oceanic boundlessness’, Anxiety, MEQ-30 | AUDITORY ALTERATION | LMM analysis revealed significant increases on the 5D-ASC subscales ‘Oceanic boundlessness’ and ‘Visual restructuralization’ for all doses compared with placebo. There were significant increases for Dose 2, 3 and 4 compared with placebo on the 5D-ASC subscale ‘Dread of ego-dissolution’, and for Dose 2 and 3 compared wi... | PMC10851633 |
Dynamic subjective effects | ’ | Retrospective assessment of different dimensions of the experience showed that participants’ experience of ‘Immersion’ and ‘Visual imagery’ largely followed subjective intensity scores over time, whereas ‘Entity encounters’ increased during the latter part of the infusion on Doses 3 and 4. Participants experienced mini... | PMC10851633 | |
Heart rate | Changes in HR following DMT dosing with respect to placebo are shown in Acute changes in HR following continuous infusions of placebo and different doses of DMT (minutes 0–30). While the initial period of DMT administration is associated with an elevated HR, this then returns to baseline levels and stabilises. Values a... | PMC10851633 | ||
Plasma DMT concentrations | Plasma concentrations of DMT over time for all doses of DMT are shown in DMT plasma concentrations after administration of DMT fumarate IV bolus dose followed by constant-rate infusion at four dose levels (minutes 0–30). Plasma concentrations peak after bolus IV injection and before the end of the continuous IV infusio... | PMC10851633 | ||
Discussion | reduction of sensory effects, Anxiety, anxiety, Disembodiment’, ’, MEQ-30 | EFFECTS INCREASED, ADVERSE EFFECTS, ADVERSE EVENTS, AUDITORY ALTERATION | The present dose-response study tested a novel methodology designed to extend the typically transient DMT experience via continuous IV infusion. This was combined with a bolus loading dose aiming to achieve prolonged effects within a short time span. Our results showed that IV infusions of DMT – at doses ranging from 6... | PMC10851633 |
Supplemental Material | PMC10851633 | |||
References | PMC10851633 | |||
INTRODUCTION | cancers, breast cancer, cancer, Breast cancer, deaths | CANCERS, BREAST CANCER, INFLAMMATION, CANCER, BREAST CANCER, NODE-POSITIVE BREAST CANCER | A practice-changing, randomized, controlled clinical study established that preoperative hydroxyprogesterone administration improves disease-free and overall survival in patients with node-positive breast cancer. This research perspective summarizes evidences from our studies that preoperative hydroxyprogesterone admin... | PMC10317070 |
Progesterone regulates | toxicity, PR-positive, PR-negative breast cancer, breast cancer | PR-NEGATIVE BREAST CANCER, BREAST CANCER | Preoperative hormonal treatments, as opposed to neoadjuvant chemotherapy, are simpler to administer, easier to monitor, less expensive, and cause less toxicity [In a separate study, we conducted functional analysis of the components found to be significantly altered after performing an integrated genomic profiling of a... | PMC10317070 |
An integrated representation of the multifaceted effects of progesterone in breast cancer. | breast cancer | INFLAMMATORY RESPONSE, CURB, BREAST CANCER | A schematic representation to describe the molecular mechanisms by which progesterone acts to curb cellular stress response and promote cell survival in breast cancer cells. Whole transcriptomic studies (represented by dotted lines) suggest that progesterone downregulates genes involved in the inflammatory response and... | PMC10317070 |
Progesterone modulates the | breast cancer | Several studies have identified the regulatory functions of noncoding microRNAs and long noncoding RNAs (lncRNAs) in breast cancer progression [In a recent study, we described the regulatory role of noncoding RNAs in response to progesterone to mediate the cellular changes [ | PMC10317070 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.